Human immunodeficiency virus type 1 viral protein R mRNA (HIV-1 Vpr mRNA)

Human immunodeficiency virus type 1 (HIV-1) Viral protein R (Vpr) mRNA is the transcript responsible for the synthesis of the Vpr accessory protein, a critical factor in viral pathogenesis [1]. Vpr is a 96-amino acid protein that facilitates the nuclear import of the viral pre-integration complex (PIC) in non-dividing cells, such as macrophages, and induces G2/M cell cycle arrest and apoptosis in infected T-cells [2, 3]. By targeting the Vpr mRNA using RNA interference (RNAi) or antisense technologies, researchers aim to prevent the production of the Vpr protein, thereby reducing viral replication and associated cytopathic effects [4]. Although no drugs targeting Vpr mRNA are currently FDA-approved, it remains a significant area of investigation for gene-silencing therapies designed to complement existing antiretroviral treatments [5]. Such approaches could potentially address viral reservoirs and the chronic immune activation driven by accessory proteins [2]. (Sources: [1] UniProt P0C6B8; [2] Retrovirology 2011, 8:11; [3] Gene 2014, 547(1):1-14; [4] FEBS Lett 2007, 581(6):1117-22; [5] Curr Top Microbiol Immunol 2009, 339:1-28).

Other names

Vpr mRNAHIV-1 vpr transcriptViral protein R transcriptHIV-1 vpr gene transcript

Inhibition of protein translation through RNA interference (RNAi) or antisense-mediated degradation of the mRNA transcript.